Stock Track | STAAR Surgical Soars 12.28% Post-Market on Strong Q1 Earnings Beat and China-Led Sales Surge

Stock Track08:07

STAAR Surgical Company's stock surged 12.28% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.

The intraocular lens maker reported a return to profitability with Q1 earnings of $0.10 per diluted share, beating the consensus estimate which anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.

Gross margin improved substantially to 73.6% from 65.8% a year earlier, driven by manufacturing efficiencies and lower costs. Management expressed confidence in consistent, profitable growth for 2026, with plans for its Swiss facility to supply all lenses shipped to China, thereby avoiding import tariffs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129541319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 08:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129541319","market":"hk","top_or_hot":-1,"title":"Stock Track | STAAR Surgical Soars 12.28% Post-Market on Strong Q1 Earnings Beat and China-Led Sales Surge","media":"Stock Track","content":"<p>STAAR Surgical Company's stock surged 12.28% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.</p><p>The intraocular lens maker reported a return to profitability with Q1 earnings of $0.10 per diluted share, beating the consensus estimate which anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.</p><p>Gross margin improved substantially to 73.6% from 65.8% a year earlier, driven by manufacturing efficiencies and lower costs. Management expressed confidence in consistent, profitable growth for 2026, with plans for its Swiss facility to supply all lenses shipped to China, thereby avoiding import tariffs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | STAAR Surgical Soars 12.28% Post-Market on Strong Q1 Earnings Beat and China-Led Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | STAAR Surgical Soars 12.28% Post-Market on Strong Q1 Earnings Beat and China-Led Sales Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-14 08:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>STAAR Surgical Company's stock surged 12.28% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.</p><p>The intraocular lens maker reported a return to profitability with Q1 earnings of $0.10 per diluted share, beating the consensus estimate which anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.</p><p>Gross margin improved substantially to 73.6% from 65.8% a year earlier, driven by manufacturing efficiencies and lower costs. Management expressed confidence in consistent, profitable growth for 2026, with plans for its Swiss facility to supply all lenses shipped to China, thereby avoiding import tariffs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STAA","symbol_name":"STAAR Surgical Company","start_time":0,"source_url":"","article_id":"1129541319","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129541319","pubTimestamp":1778717239,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"STAAR Surgical Company's stock surged 12.28% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STAA":"STAAR Surgical Company"},"translate_title":"个股追踪|STAAR Surgical盘后飙升12.28%，因Q1盈利强劲超出预期和中国主导的销售激增","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":1},"content_text":"STAAR Surgical Company's stock surged 12.28% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.The intraocular lens maker reported a return to profitability with Q1 earnings of $0.10 per diluted share, beating the consensus estimate which anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.Gross margin improved substantially to 73.6% from 65.8% a year earlier, driven by manufacturing efficiencies and lower costs. Management expressed confidence in consistent, profitable growth for 2026, with plans for its Swiss facility to supply all lenses shipped to China, thereby avoiding import tariffs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129541319","isCrawlerRequest":true}